Volition announces the launch of the Nu.Q® Vet Cancer Screening Test in the US and Europe through Heska’s Reference Laboratory

Henderson, Nev., November 3, 2022 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, announced the upcoming launch of its Nu.Q® Vet Cancer Screening Test across the United States. Europe by Heska Corporation (NASDAQ: HSKA) (“Heska”), a leading global provider of advanced veterinary diagnostics through Heska’s Veterinary Diagnostic Laboratories.

Steve IsleChief Commercial Officer and President of Heska, a scil animal company, said, “Our team has been working closely with Volition for the past six months and we are excited to launch Volition’s Nu.Q® vet cancer screening test in the US and in the coming Able to declare. ON Europe Expected in the coming weeks by our veterinary diagnostic laboratory Accurate, cost-effective, and non-invasive diagnostics for cancer screening and monitoring in canines are an ideal fit within the expanding portfolio of best-in-class solutions. This is an important achievement in our transformational work together as we move towards the launch of our flagship point of care solution, expected in 2023.”

Dr. Tom ButeraChief Executive Officer of Volition Veterinary Diagnostics Development LLC said, “We are thrilled to work alongside Heska and support the launch of the Nu.Q® Vet Cancer Screening Test. United States And Europe. This is another important milestone for us, as we move forward with our goal of ensuring that as many veterinarians as possible have access to our Nu.Q® Vet Cancer Screening Test for pets and the pet owners who trust them.

“There are about 84 million pet dogs United States And nearly half of all dogs will have at least one veterinary care visit per year. Implementing the Nu.Q® Vet Cancer Screening Test at annual wellness visits can help detect cancer at an early stage, even before symptoms appear, allowing for effective treatment and a better chance of improved outcomes.”

Willpower is developing simple, easy-to-use, affordable blood tests to help diagnose and monitor a variety of life-changing diseases, including cancer, in both humans and animals. For more information on Volition’s Nu.Q® technology visit: www.volition.com.

The story continues

Editors note:

1. The sign of desire is exclusive $28 million License and supply agreement with Heska Corporation to distribute the Nu.Q® Vet Cancer Screening Test March 29 2022

2. Results from a clinical study conducted by Volition and Professor Wilson-Robles and team Texas A&M UniversityPeer-reviewed and published August 2022showed that:

About Heska

Heska Corporation (NASDAQ: HSKA ) manufactures, develops and sells advanced veterinary diagnostics and specialty healthcare products through its two business divisions: North America and international. Both segments include point-of-care lab testing instruments and consumables, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm prevention products. The North America The segment includes private label vaccine and pharmaceutical manufacturing under third-party contracts and channels, primarily for livestock animal health. Please visit for more information www.heska.com.

About willpower

Volition is a multinational epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a variety of life-changing diseases, including cancer and NETosis. associated diseases. As sepsis and COVID-19. Early diagnosis and monitoring can not only prolong patients’ lives but also improve their quality of life. The tests are based on the science of nucleosomics™, which is the practice of detecting and measuring nucleosomes in the bloodstream or other bodily fluids – an indication that disease is present.

Volition’s research and development activities are focused Belgiumincluding an innovation laboratory and office and additional offices in the United States London And Singapore.

Content found at Volition’s and Heska’s website addresses is not incorporated by reference into this document and should not be considered a part of this document. Such website addresses are included in this document only as an inactive textual reference.

Media Search:

Lewis Bachelor/Debra DouglasVolition, [email protected] +44 (0)7557 774620

John AgardHeska, [email protected] +1 970-617-8399

Safe Harbor Statement

Statements in this press release may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended, as to the risks and issues involved. Uncertainties that could cause actual results to differ materially from anticipated or anticipated statements. Words such as “anticipate,” “anticipate,” “will,” “plan,” “goal,” “goal,” “believe,” “expect,” “estimate,” “optimize,” “potential,” “target” “”suggests,” “will,” “will,” “should,” “may,” “will” and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other things, Volition’s estimated market opportunities, product launches including timing, Volition’s blood-based diagnostics, Volition’s performance, Volition’s expectations related to potential benefits under the license and supply agreement with Heska, and disease monitoring tests, and the early detection of cancer and other diseases as well as a diagnostic, prognostic or Volition’s ability to develop and successfully commercialize such test platforms to serve as disease monitoring tools. Volition’s actual results could differ materially from those indicated in these forward-looking statements due to many risks and uncertainties, including, without limitation, , including the results of studies testing its test performance. For example, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its operations plan. Other risks and uncertainties include Volition’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products; to adopt products in Volition’s development pipeline or to develop any other diagnostic, prognostic or disease monitoring products; Will’s failure to ensure adequate intellectual property protection; Volition will face intense competition and Volition’s intended products may become obsolete due to the highly competitive nature of the diagnostic and disease monitoring market and its rapid technological change; slowdown in domestic and foreign economies; and other risks identified in Volition’s most recent annual reports on Form 10-K and quarterly reports on Form 10-Q, as well as in other documents that Volition files with the Securities and Exchange Commission. These statements are based, in part, on assumptions made by management on current expectations, assumptions and assumptions about Volition’s business. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release and, except as required by law, Volition undertakes no obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names mentioned in this press release are the property of their respective owners.

See original content: https://www.prnewswire.com/news-releases/volition-announces-the-launch-of-the-nuq-vet-cancer-screening-test-in-the-us-and-europe- via-heskus-reference-laboratories-301667561.html

Source VolitionRx